



GBT to Present at the 38th Annual J.P. Morgan Healthcare Conference

January 7, 2020

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020, at 4:00 p.m. Pacific Time.

The presentation and Q&A session will be webcast live from GBT's website at www.gbt.com in the [Investors](#) section. A replay of the webcast will be archived and available for replay for one month following the event.

About GBT

GBT is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta™ (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT's drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter [@GBT_news](#).

Contact Information:

Steven Immergut (media)

GBT

650-410-3258

media@gbt.com

Stephanie Yao (investors)

GBT

650-741-7730

investor@gbt.com



Source: Global Blood Therapeutics, Inc.